161 related articles for article (PubMed ID: 36882315)
1. Analysis of PRAME immunocytochemistry in 109 acral malignant melanoma in situ.
Miao QJ; Zang J; Shao XB; Sun JF; Chen YP; Chen H
J Clin Pathol; 2024 May; 77(6):417-420. PubMed ID: 36882315
[TBL] [Abstract][Full Text] [Related]
2. Comparison of S100A8 and PRAME as biomarkers for distinguishing melanoma from melanocytic naevus: a case-control analysis.
Hai J; Meyer SN; Wong SL; Li Y; Simmons E; Miglioretti D; Fung MA; Kiuru M
Clin Exp Dermatol; 2024 May; 49(6):584-590. PubMed ID: 38306117
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions.
Rothrock AT; Torres-Cabala CA; Milton DR; Cho WC; Nagarajan P; Vanderbeck K; Curry JL; Ivan D; Prieto VG; Aung PP
J Cutan Pathol; 2022 Oct; 49(10):859-867. PubMed ID: 35794643
[TBL] [Abstract][Full Text] [Related]
4. Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi.
Hu J; Cai X; Lv JJ; Wan XC; Zeng XY; Feng ML; Dai B; Kong YY
Hum Pathol; 2022 Feb; 120():9-17. PubMed ID: 34800527
[TBL] [Abstract][Full Text] [Related]
5. Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions.
Santandrea G; Valli R; Zanetti E; Ragazzi M; Pampena R; Longo C; Lai M; Piana S; Cesinaro AM
Am J Surg Pathol; 2022 May; 46(5):579-590. PubMed ID: 35275883
[TBL] [Abstract][Full Text] [Related]
6. Refining the application of PRAME-a useful marker in high CSD and acral melanoma subtypes.
Wakefield C; O'Keefe L; Heffron CCBB
Virchows Arch; 2023 Dec; 483(6):847-854. PubMed ID: 37723345
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Melanocyte-Associated Immunohistochemical Markers in Acral Lentiginous Melanoma and Acral Benign Nevi.
Kim JC; Choi JW; Kim YC
Am J Dermatopathol; 2023 Nov; 45(11):748-752. PubMed ID: 37856738
[TBL] [Abstract][Full Text] [Related]
8. Performance of PRAME immunohistochemistry compared with that of c-Kit, c-Myc, or cyclin D1 for the diagnosis of acral melanocytic tumors.
Jung JM; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
Pathol Int; 2023 Jan; 73(1):27-36. PubMed ID: 36468840
[TBL] [Abstract][Full Text] [Related]
9. PRAME Immunohistochemistry for Distinguishing Vulvar and Vaginal Melanoma From Benign Melanocytic Nevi.
Martin SD; Martin KC; Gilks CB; Crawford RI; Hoang LN
Int J Gynecol Pathol; 2023 Dec; ():. PubMed ID: 38085951
[TBL] [Abstract][Full Text] [Related]
10. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
11. PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions.
Mudhar HS; Milman T; Stevenson S; Watson M; Kim J; Magan T; Salvi SM; Harley U; Lally SE; Shields CL
Hum Pathol; 2023 Apr; 134():1-18. PubMed ID: 36804828
[TBL] [Abstract][Full Text] [Related]
12. PRAME immunohistochemistry of spitzoid neoplasms.
Koh SS; Lau SK; Scapa JV; Cassarino DS
J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of Preferentially Expressed Antigen in Melanoma Immunohistochemistry and Diagnostic Gene Expression-Profiling Assay in Challenging Melanocytic Proliferations.
Casillas AC; Muhlbauer A; Barragan VA; Jefferson I; Speiser JJ
Am J Dermatopathol; 2024 Mar; 46(3):137-146. PubMed ID: 38354382
[TBL] [Abstract][Full Text] [Related]
14. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
[TBL] [Abstract][Full Text] [Related]
15. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
Lohman ME; Steen AJ; Grekin RC; North JP
J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
[TBL] [Abstract][Full Text] [Related]
16. PRAME-negativity in sclerosing nevi with pseudomelanomatous features supports classification as an indolent lesion.
Tang H; McNiff JM; Glusac EJ; Ko C
J Cutan Pathol; 2023 Nov; 50(11):1001-1005. PubMed ID: 37565491
[TBL] [Abstract][Full Text] [Related]
17. PRAME expression in melanocytic lesions of the nail.
Parra O; Linos K; Li Z; Yan S
J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Lezcano C; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
[TBL] [Abstract][Full Text] [Related]
19. PRAME Immunoexpression in 275 Cutaneous Melanocytic Lesions: A Double Institutional Experience.
Cazzato G; Cascardi E; Colagrande A; Belsito V; Lospalluti L; Foti C; Arezzo F; Dellino M; Casatta N; Lupo C; Buongiorno L; Stellacci A; Marrone M; Ingravallo G; Maiorano E; Resta L
Diagnostics (Basel); 2022 Sep; 12(9):. PubMed ID: 36140597
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry for PRAME in Dermatopathology.
Lezcano C; Jungbluth AA; Busam KJ
Am J Dermatopathol; 2023 Nov; 45(11):733-747. PubMed ID: 37856737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
